In medicine, the digestive tract (or ‘gut’) and the brain have long been treated as two separate entities – but research from the past few decades has discovered strong interconnections between the two. Recently, as scientists have advanced our understanding of the mechanisms by which the gut and the brain communicate, they have identified microorganisms...

At Pharmabiotics 2021 Conference & Partnering, Adrien Nivoliez, Biose Industrie CEO, held an Interactive Roundtable Discussion called Microbiome Therapeutics – the investment cycle from discovery to commercialization. Nivoliez spoke with Denise Kelly, Investment Advisor at Seventure Partners, and Paul Wagner, President & CEO of Forte Biosciences, about how microbiome companies can succeed in getting the...

Using live microorganisms to enhance response to cancer immunotherapies is finally within reach.   Cancer is the world’s leading cause of death, affecting people of all ages and socio-economic groups. Although many types of cancer exist, what they have in common is the immune system’s failure to recognize or eliminate cancer cells, allowing them to...

Hundreds of companies around the world are currently working on how to leverage human microbiome research for new clinical solutions – with at least €900M invested in microbiome-focused companies in 2020. The Microbiome Movement Drug Development Summit Europe, held 27-29thJanuary as a digital event, provided an opportunity to hear from some of the leading companies and learn...

Boston is one of the top global hubs for biotechnology companies developing live biotherapeutic products (LBPs), and many of these companies seek out the expertise of the world leading CDMO, France’s Biose Industrie. As of September, 2020, Biose Industrie’s manufacturing expertise will be even closer to these US organizations: the company has established a new office...

Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), announced today the advancement to large-scale production of BMC128, its Live Bacterial Product (LBP) candidate consortium. The microbes, which will be produced in large-scale are expected to support Biomica’s first-in-man proof-of-concept clinical trials for its immuno-oncology...

A company that supports the process development and manufacturing of live biotherapeutic products (LBPs) needs to know bacteria inside out: not just the potential therapeutic effects of the strains, but how the strains behave under different conditions and in different contexts. A better understanding of mechanisms of action, after all, allows better optimization of the...

Aurillac, July 16, 2020 – Biose Industrie announced today the closing of a €30 million funding round led by Cathay Capital, alongside the company’s management team, banking partners and the Auvergne-Rhône-Alpes region. Thanks to this funding found, Biose Industrie will benefit from Cathay Capital’s support as it accelerates its development and strengthens its leadership position...